# Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

> **NCT04215016** · PHASE1 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

## Interventions

- **BIOLOGICAL:** Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

## Key facts

- **NCT ID:** NCT04215016
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215016, "Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04215016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*